Lyell Immunopharma's CAR T Therapy Shows Astonishing 94% Response Rate in Lymphoma Trial
Lyell Immunopharma Announces Promising Clinical Results
Lyell Immunopharma (LYEL) has unveiled encouraging initial data from its Phase 1-2 study of IMPT-314. The positive results were shared at the 66th American Society of Hematology Annual Meeting. This announcement marks a significant step forward in the development of treatments for large B-cell lymphoma.
Introducing IMPT-314: A Dual-Targeting CAR T-Cell Therapy
IMPT-314 is an innovative CAR T-cell therapy designed to target both CD19 and CD20 antigens. This dual-targeting approach aims to enhance the effectiveness of treatment for aggressive B-cell non-Hodgkin lymphoma. By addressing multiple targets, IMPT-314 seeks to overcome challenges like antigen escape and variable CD19 expression.
Outstanding Efficacy in Clinical Trials
In the study, 23 patients with relapsed or refractory large B-cell lymphoma received IMPT-314. Among the 17 patients evaluable for efficacy, an impressive 94% showed an overall response. Notably, 71% achieved a complete remission within three months, and the majority remained in response at the last follow-up after a median of 6.3 months.
Safety Profile Highlights
The safety data from the trial is equally encouraging. No Grade 3 or higher cytokine release syndrome (CRS) was reported among the 23 patients. Additionally, Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in only 13% of patients, with a swift median resolution time of five days. Most patients improved to Grade 2 or lower with standard treatment.
Pharmacokinetics and T-Cell Characteristics
IMPT-314 demonstrated strong pharmacokinetic properties, with peak cell expansion occurring between days 7 and 28 post-infusion. The final drug product maintained the desired naive and central memory T-cell phenotypes, which are linked to better overall survival outcomes in CAR T-cell therapies. These characteristics underline the robustness of IMPT-314 in clinical settings.
Future Directions and Upcoming Trials
Buoyed by the strong initial data, Lyell Immunopharma plans to launch a pivotal trial of IMPT-314 in 2025. This trial will focus on CAR T-naive patients with large B-cell lymphoma in the third-line or higher setting. Additionally, the company is exploring the use of IMPT-314 in the second-line setting within the ongoing Phase 1-2 trial, aiming to broaden the therapy's applicability.
Conclusion
Lyell Immunopharma's IMPT-314 is emerging as a promising next-generation CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma. With high response rates and a favorable safety profile, IMPT-314 holds strong potential to improve patient outcomes. The upcoming trials are highly anticipated and could mark a significant advancement in cancer treatment.
Read the full article here:
businessinsider.com